MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Nephros Retained Earnings 2011-2026 | NEPH
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Nephros
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -144 M | -143 M | -136 M | -132 M | -127 M | -124 M | -121 M | -120 M | -117 M | -114 M | -101 M | -97.5 M | -94.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -94.3 M | -144 M | -121 M |
Quarterly Retained Earnings Nephros
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -143 M | -144 M | -144 M | -144 M | -145 M | -145 M | -145 M | -144 M | -144 M | -144 M | -143 M | -143 M | -142 M | -139 M | -138 M | -136 M | -135 M | -134 M | -132 M | -132 M | -132 M | -132 M | -132 M | -127 M | -127 M | -127 M | -127 M | -124 M | -124 M | -124 M | -124 M | -121 M | -121 M | -121 M | -121 M | -120 M | -120 M | -120 M | -120 M | -117 M | -117 M | -117 M | -117 M | -114 M | -114 M | -114 M | -114 M | -107 M | -101 M | -101 M | -101 M | -108 M | -97.5 M | -97.5 M | -97.5 M | -101 M | -94.3 M | -94.3 M | -94.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -94.3 M | -145 M | -124 M |
Retained Earnings of other stocks in the Medical instruments industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
382 K | - | - | $ 810 M |  USA |
 |
Luminex Corporation
LMNX
|
83.8 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-120 M | - | -9.52 % | $ 20.6 M | USA |
 |
iRhythm Technologies
IRTC
|
-803 M | $ 126.93 | 3.74 % | $ 4.06 B | USA |
 |
Alcon
ALC
|
19.4 B | $ 76.13 | 0.46 % | $ 40.4 B |  Schweiz |
 |
Ekso Bionics Holdings
EKSO
|
-262 M | $ 10.93 | -0.55 % | $ 26.5 M | USA |
 |
The Cooper Companies
COO
|
7.64 B | $ 64.3 | -0.19 % | $ 12.8 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
-223 M | - | - | $ 955 M | USA |
 |
Repro Med Systems
KRMD
|
-32 M | $ 4.03 | 1.77 % | $ 186 M | USA |
 |
Cantel Medical Corp.
CMD
|
548 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
-11.9 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.13 B | - | -0.05 % | $ 10.3 B | USA |
 |
Microbot Medical
MBOT
|
-104 M | $ 2.17 | -1.36 % | $ 99.4 M |  Israel |
 |
Milestone Scientific
MLSS
|
-134 M | $ 0.32 | 1.15 % | $ 26.3 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
1.13 B | - | -0.02 % | $ 16.3 B | USA |
 |
Haemonetics Corporation
HAE
|
352 M | $ 60.81 | 1.38 % | $ 3.06 B | USA |
 |
electroCore
ECOR
|
-191 M | $ 6.07 | -1.7 % | $ 51.5 K | USA |
 |
ICU Medical
ICUI
|
691 M | $ 122.32 | -2.0 % | $ 3.01 B | USA |
 |
Envista Holdings Corporation
NVST
|
-440 M | $ 26.79 | - | $ 4.5 B | USA |
 |
Isoray
ISR
|
-335 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
7.01 B | $ 471.29 | -2.27 % | $ 168 B | USA |
 |
Glaukos Corporation
GKOS
|
-599 M | $ 121.88 | 0.18 % | $ 5.9 B | USA |
 |
STERIS plc
STE
|
2.48 B | $ 221.92 | 0.08 % | $ 21.9 B | USA |
 |
Teleflex Incorporated
TFX
|
3.15 B | $ 136.38 | -0.13 % | $ 6.09 B | USA |
 |
Masimo Corporation
MASI
|
1.49 B | $ 178.6 | -0.02 % | $ 9.52 B | USA |
 |
InfuSystem Holdings
INFU
|
-59.3 M | $ 10.6 | 2.71 % | $ 219 M | USA |
 |
Merit Medical Systems
MMSI
|
824 M | $ 67.27 | -1.91 % | $ 3.98 B | USA |
 |
Utah Medical Products
UTMD
|
129 M | $ 67.07 | -0.15 % | $ 217 M | USA |
 |
West Pharmaceutical Services
WST
|
4.37 B | $ 301.01 | -1.6 % | $ 21.8 B | USA |
 |
Pulse Biosciences
PLSE
|
-463 M | $ 22.39 | -2.74 % | $ 1.51 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-1.56 B | $ 11.9 | -0.13 % | $ 2.37 B | USA |
 |
Retractable Technologies
RVP
|
13.9 M | $ 0.63 | -1.72 % | $ 18.9 M | USA |
 |
Pro-Dex
PDEX
|
35.9 M | $ 51.94 | -0.32 % | $ 171 M | USA |
 |
LeMaitre Vascular
LMAT
|
185 M | $ 115.31 | 1.64 % | $ 2.61 B | USA |
 |
Predictive Oncology
POAI
|
-414 M | - | - | $ 31.1 M | USA |
 |
STAAR Surgical Company
STAA
|
-148 M | $ 26.2 | 2.06 % | $ 1.3 B | USA |
 |
BioLife Solutions
BLFS
|
-335 M | $ 21.31 | -0.33 % | $ 982 M | USA |
 |
Stereotaxis
STXS
|
-583 M | $ 1.94 | 0.26 % | $ 176 M | USA |
 |
Baxter International
BAX
|
13.7 B | $ 18.46 | 1.68 % | $ 9.47 B | USA |
 |
ResMed
RMD
|
3.61 B | $ 222.96 | 1.47 % | $ 32.6 B | USA |
 |
AtriCure
ATRC
|
-413 M | $ 29.06 | -0.75 % | $ 1.39 B | USA |
 |
Harvard Bioscience
HBIO
|
-215 M | $ 6.56 | -4.37 % | $ 291 M | USA |
 |
NeuroMetrix
NURO
|
-218 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
-429 M | $ 11.01 | -0.81 % | $ 450 M | USA |
 |
Becton, Dickinson and Company
BDX
|
16.6 B | $ 150.72 | -0.92 % | $ 43.4 B | USA |
 |
OraSure Technologies
OSUR
|
-172 M | $ 2.97 | -1.17 % | $ 218 M | USA |
 |
Repligen Corporation
RGEN
|
433 M | $ 118.39 | 0.67 % | $ 6.6 M | USA |